A few years ago, compounded GLP-1 meant one thing: a vial and a syringe. In 2026, patients choosing compounded semaglutide or tirzepatide have multiple format options—subcutaneous injections, sublingual drops, sublingual troches (lozenges), and oral dissolving tablets.
Each format involves trade-offs across bioavailability, convenience, cost, shelf life, and side effect profile. This guide breaks down what those trade-offs actually look like so you can have an informed conversation with your provider about which format makes sense for you.
The Core Trade-Off: Bioavailability
Bioavailability is the percentage of the active drug that reaches your bloodstream and becomes pharmacologically active. This is the single most important difference between formats, and it drives everything else—dosing, cost per effective milligram, and clinical outcomes.
| Format | Estimated Bioavailability | Typical Dosing | Clinical Evidence Level |
|---|---|---|---|
| Subcutaneous injection | ~89–100% | Once weekly | Strong (based on FDA-approved formulations) |
| Sublingual drops | Estimated 15–30% | Daily | Limited; no large published trials specific to compounded sublingual semaglutide |
| Sublingual troches | Estimated 10–25% | Daily | Limited; primarily anecdotal and provider-reported |
| Oral dissolving tablets | Estimated 5–15% | Daily | Very limited for compounded versions; FDA-approved oral Wegovy uses proprietary absorption technology |
Lower bioavailability means higher doses of raw semaglutide are needed to achieve equivalent blood levels. A weekly 1.0mg injection might require a daily sublingual dose of 3–5mg or more to achieve comparable effect—which means more active ingredient per month, which affects cost.
Format-by-Format Breakdown
💉 Subcutaneous Injection
The clinical gold standard. Once-weekly self-injection using a syringe or pre-filled device.
This is the format with the most clinical evidence behind it. All major GLP-1 weight loss trials (STEP 1–5 for semaglutide, SURMOUNT 1–4 for tirzepatide) used subcutaneous injection. It delivers the highest bioavailability, meaning the dose your provider prescribes is very close to what your body actually absorbs.
Typical cost: $130–$299/month depending on provider and dose.
Shelf life: 30–90 days refrigerated for liquid vials; months for lyophilized powder (pre-reconstitution).
- Highest, most predictable bioavailability
- Once-weekly dosing
- Strongest clinical evidence base
- Most providers offer this format
- Dose-response well understood
- Requires self-injection (needle)
- Cold-chain storage required
- Injection site reactions possible
- Dosing errors with multi-dose vials (FDA has flagged this)
- Not suitable for needle-phobic patients
💧 Sublingual Drops
Liquid placed under the tongue and held for 60–90 seconds. Daily dosing.
Sublingual delivery bypasses the digestive system by absorbing medication through the mucous membranes under the tongue, sending it directly into the bloodstream. This avoids the harsh gastric environment that destroys most oral peptides. However, absorption rates are variable and highly dependent on technique—swallowing too soon, eating or drinking beforehand, or not holding the liquid long enough all reduce absorption.
Typical cost: Comparable to or slightly less than injectable, but higher effective cost per absorbed milligram due to lower bioavailability.
Shelf life: 30–90 days depending on formulation and preservatives.
- No needles
- Better absorption than oral (bypasses GI tract)
- Easier to travel with
- No sharps disposal needed
- Daily dosing (vs weekly for injectable)
- Variable absorption based on technique
- Limited clinical trial data
- Must avoid eating/drinking for 30 min after
- Higher dose of raw ingredient needed
💊 Sublingual Troches (Lozenges)
A solid lozenge that dissolves slowly under or against the tongue. Daily dosing.
Troches work on the same principle as sublingual drops—absorption through oral mucous membranes—but in a solid format that dissolves over several minutes. Some patients find troches easier to use consistently because there’s no liquid to measure. However, the slower dissolution means some of the medication is inevitably swallowed rather than absorbed sublingually, reducing effective bioavailability compared to drops.
Typical cost: Similar range to drops. Available from providers like SHED that offer multi-format options.
Shelf life: Potentially longer than liquid formats. Non-aqueous troches may receive BUDs up to 180 days under USP <795>.
- No needles, no liquid measuring
- Potentially longer shelf life than liquids
- Easier to transport and store
- Discreet to use
- Lowest sublingual bioavailability (partial swallowing)
- Daily dosing
- Very limited clinical evidence
- Taste can be unpleasant
- Fewer providers offer this format
💊 Oral Dissolving Tablets
Swallowed tablets or buccal tablets that dissolve in the mouth. Daily dosing.
Oral compounded semaglutide tablets face the biggest bioavailability challenge. Peptide drugs like semaglutide are largely destroyed by stomach acid and digestive enzymes. FDA-approved oral semaglutide (Rybelsus, oral Wegovy) uses a patented absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) that protects the peptide and promotes absorption. Compounded oral tablets do not use SNAC—they rely on alternative excipients and delivery strategies, resulting in lower and less predictable absorption.
Typical cost: Varies widely. May be cheaper per unit but requires higher doses.
Shelf life: Non-aqueous tablets can have BUDs up to 180 days—the longest of any compounded format.
- Most familiar format (just take a pill)
- No needles, no sublingual technique
- Longest potential shelf life
- Easiest to travel with
- Lowest bioavailability of all formats
- No SNAC absorption enhancer (unlike brand-name)
- Highest dose of raw ingredient needed
- Must take on empty stomach with minimal water
- Least clinical evidence for compounded versions
Which Format Should You Choose?
Choose sublingual drops if: You’re needle-averse but willing to commit to daily dosing and can follow proper sublingual technique consistently. Better absorption than swallowed tablets.
Choose troches/tablets if: Convenience and portability are your top priority, and you accept the trade-off of lower (and less predictable) bioavailability. May also be preferred for shelf-life reasons if you want to stock ahead.
What About Brand-Name Oral Semaglutide?
It’s worth noting that FDA-approved oral semaglutide now exists in two forms: Rybelsus (approved for type 2 diabetes) and oral Wegovy (approved late 2025 for weight management). These use Novo Nordisk’s patented SNAC technology, which dramatically improves oral peptide absorption. Oral Wegovy is currently available at $149/month for lower doses through the manufacturer’s self-pay program.
If your primary motivation for non-injectable GLP-1 is needle avoidance rather than cost, FDA-approved oral Wegovy may be worth discussing with your provider. It offers the regulatory certainty of FDA approval plus a proven absorption-enhancing technology that compounded oral tablets lack.
Compare Providers by Format
See which providers offer injectable, sublingual, and oral options—with pricing for each.
Compare Providers →Bottom Line
For most patients, subcutaneous injection remains the recommended format based on clinical evidence, bioavailability, and cost-effectiveness per absorbed milligram. Sublingual formats offer a reasonable needle-free alternative for patients willing to accept daily dosing and somewhat lower absorption. Oral tablets are the most convenient but carry the most uncertainty about effective absorption without SNAC technology.
Whichever format you choose, the most important step is discussing it with your prescribing provider, who can adjust dosing based on the format’s expected bioavailability and monitor your response over time.